Pharmafile Logo
Pharmafocus logo
Advanced Search

AstraZeneca

Showing 15 posts of 749 posts found.

dado_ruvic-illustration-reuters

Interim analysis for AstraZeneca’s COVID-19 vaccine finds 70% average efficacy

November 23, 2020
Research and Development, Sales and Marketing AstraZeneca, COVID-19, Vaccine

Hot on the heels of Moderna and Pfizer/BioNTech who both have released very promising data for their mRNA COVID-19 vaccine …

News
1200px-astrazeneca_hq_in_cambridge_uk

AstraZeneca’s Calquence fails to improve survival rates in coronavirus patients

November 12, 2020
Business Services AZ, AstraZeneca, Calquence

AstraZeneca’s Calquence has failed to improve survival rates and prevent lung failure in patients hospitalised with COVID-19.  Calquence (acalabrutinib) is …

News
astrazeneca_sign_sky

Argentina secures 22 million COVID-19 vaccine doses from AstraZeneca and Oxford Uni

November 9, 2020
Manufacturing and Production, Sales and Marketing Argentina, AstraZeneca, COVID-19, Vaccine

AstraZeneca has committed to an agreement to deliver 22 million doses of its COVID-19 vaccine candidate, co-developed in partnership with …

News
shutter

AstraZeneca’s Brilinta combo reduces rate of disabling stroke or death in stroke patients, according to Phase 3 data

November 9, 2020
Research and Development, Sales and Marketing AstraZeneca, Brilinta, pharma

AstraZeneca has unveiled new Phase 3 data for Brilinta (ticagrelor) as a treatment for patients who have suffered an acute …

News
shutterstock_87495637

AstraZeneca jettisons two heart drugs to Cheplapharm in $400m deal

October 30, 2020
Manufacturing and Production, Medical Communications, Sales and Marketing AstraZeneca, Cheplapharm

AstraZeneca is set to sell the rights to its AT1 subtype angiotensin II receptor antagonist Atacand (candesartan cilexetil) and Atacand …

News
astrazeneca-sign

AstraZeneca’s COVID-19 vaccine generates immune response in both old and young participants

October 26, 2020
Research and Development, Sales and Marketing AstraZeneca, COVID-19, University of Oxford, Vaccine

AstraZeneca’s much-hyped COVID-19 vaccine candidate, AZD1222, currently in development in partnership with the University of Oxford, has shown promising immune …

News
vaccination-1215279_960_720

Spain secures 31.6 million doses of AstraZeneca’s COVID-19 vaccine

October 21, 2020
Manufacturing and Production, Research and Development AstraZeneca, COVID-19, Spain, Vaccine

AstraZeneca continues to forge agreements with national governments to deliver its vaccine against COVID-19, with Spain becoming the latest country …

News
astrazeneca-sign

FDA grants priority review to AstraZeneca’s Tagrisso as an adjuvant for early-stage EGFR-mutated non-small cell lung cancer

October 20, 2020
Manufacturing and Production, Sales and Marketing AstraZeneca, FDA, Tagrisso

The FDA has revealed its decision to grant Priority Review to AstraZeneca’s Tagrisso (osimertinib) as an adjuvant treatment of patients …

News
jnjioffice

European Commission agrees deal with Janssen for 200 million doses of its COVID-19 vaccine

October 9, 2020
Medical Communications AZ, AstraZeneca, Janssen

The European Commission has approved an agreement with Johnson & Johnson for the supply of 200 million doses of Janssen’s …

News
1

Science community calls for transparency on AstraZeneca’s halted US COVID-19 vaccine trial

September 23, 2020
Research and Development AstraZeneca, COVID-19, Vaccine

The halting of AstraZeneca’s COVID-19 vaccine trial around the world was cause for much initial concern over the eventual safety …

News
shutterstock_2

AstraZeneca and Samsung Biologics partner up in $330m manufacturing and supply deal

September 22, 2020
Manufacturing and Production AstraZeneca, Samsung BioLogics, manufacturing, pharma

AstraZeneca has announced a new global manufacturing and supply partnership with Samsung Biologics, said to be worth a potential $330.8 …

News
800px-astrazeneca_hq_in_cambridge_uk

AstraZeneca’s Lynparza recommended by the EMA for HRD-positive advanced ovarian cancer

September 21, 2020
Sales and Marketing AstraZeneca

AstraZeneca and MSD’s Lynparza (olaparib) has been recommended for marketing authorisation across the European Union for the first-line maintenance treatment …

News
shutterstock_38078521

AstraZeneca and Oxford Uni’s COVID-19 vaccine trial resumes following safety review

September 14, 2020
Research and Development, Sales and Marketing AstraZeneca, COVID-19, Oxford University, Vaccine

After sparking a wave of concern through industry and mainstream media with the news it had halted international studies investigating …

News
astrazeneca_sign_sky

NICE U-turns to approve AstraZeneca’s Tagrisso in two new lung cancer indications

September 11, 2020
Medical Communications, Sales and Marketing AstraZeneca, NICE, Tagrisso

NICE has announced the recommendation of AstraZeneca’s Tagrisso (osimertinib) for routine use on the NHS in England and Wales in …

News
800px-astrazeneca_hq_in_cambridge_uk

AstraZeneca Chief Executive says vaccine is still possible this year

September 10, 2020
Research and Development AstraZeneca, Oxford Vaccine, Vaccine, coronavirus vaccine, vaccines

Pascal Soriot, Chief Executive of AstraZeneca, said that the company’s vaccine could still be available this year, despite the clinical …

News

Latest content

FDA grants marketing authorisation to DNA test for predisposition to certain cancers

October 2, 2023

Biogen’s biosimilar Tofidence approved by FDA

October 2, 2023

Austrian state secretary to speak at FlyPharma Europe 2023

September 29, 2023

Karuna Therapeutics submits NDA to FDA for schizophrenia treatment

September 29, 2023

Kura Oncology shares preclinical data for NSCLC treatment

September 29, 2023